اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,726
تعداد مقالات31,038
تعداد مشاهده مقاله27,545,055
تعداد دریافت فایل اصل مقاله16,200,199
Khudheyer Almyah, M, Ayyob, A. N2, Al-Badran, R. A, Issa Al-Badran, A. (1401). Screening of Exons 4-9 Polymorphisms of FTO Gene in Endometrial and Ovarian Cancers. سامانه مدیریت نشریات علمی, 78(1), 185-193. doi: 10.22092/ari.2022.358486.2227
M Khudheyer Almyah; A. N2 Ayyob; R. A Al-Badran; A Issa Al-Badran. "Screening of Exons 4-9 Polymorphisms of FTO Gene in Endometrial and Ovarian Cancers". سامانه مدیریت نشریات علمی, 78, 1, 1401, 185-193. doi: 10.22092/ari.2022.358486.2227
Khudheyer Almyah, M, Ayyob, A. N2, Al-Badran, R. A, Issa Al-Badran, A. (1401). 'Screening of Exons 4-9 Polymorphisms of FTO Gene in Endometrial and Ovarian Cancers', سامانه مدیریت نشریات علمی, 78(1), pp. 185-193. doi: 10.22092/ari.2022.358486.2227
Khudheyer Almyah, M, Ayyob, A. N2, Al-Badran, R. A, Issa Al-Badran, A. Screening of Exons 4-9 Polymorphisms of FTO Gene in Endometrial and Ovarian Cancers. سامانه مدیریت نشریات علمی, 1401; 78(1): 185-193. doi: 10.22092/ari.2022.358486.2227

Screening of Exons 4-9 Polymorphisms of FTO Gene in Endometrial and Ovarian Cancers

Archives of Razi Institute
مقاله 25، دوره 78، شماره 1، فروردین و اردیبهشت 2023، صفحه 185-193    اصل مقاله (685.2 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.358486.2227
نویسندگان
M Khudheyer Almyah1؛ A. N2 Ayyob2؛ R. A Al-Badran3؛ A Issa Al-Badran* 3
1General Directorate of Education, Basra, Iraq
2Department of Biology, College of Education in Qurna, University of Basra, Basra, Iraq
3Department of Biology, College of Science, University of Basra, Basra, Iraq
چکیده
Endometrial and ovarian tumours are almost mechanistically affected by reproductive hormones. Ovarian cancer may be explained as metastatic or synchronous primary ovarian cancer, and the specific diagnosis is a challenge. This study aimed to investigate the mutations in fat mass and obesity-associated (FTO) genes and investigated the association of these mutations with the risk of endometrial and ovarian cancers as well as with cancer grade and stage. Blood samples were collected from 48 endometrial and ovarian cancer cases and 48 healthy women. Genomic DNA was extracted, and PCR was done to amplify FTO exons 4-9. Sanger sequencing identified 6 different novel mutations submitted to DDBJ: p.W278G and p.G284G in exon 4, p.S318I and p.A324G in exon 5 and two mutations in intron 4. Other mutations were also detected in FTO gene sequencing results, rs112997407 in intron 3, rs62033438, rs62033439, rs8048254 and rs8046502 in intron 4. The novel p.W278G, p.S318I and p.A324G mutations were predicted to be damaging. We did not find a significant association for all variables with cancer risk or clinical stage and grade except for rs62033438 variants, which showed a significant association with cancer grade, especially AA genotype (OR= 15, 95% CI:1.32 -169.88, P= 0.03). In conclusion, the statistical analysis did not clarify whether FTO mutations are implicated in cancer. Further studies with more samples are recommended to provide a more accurate picture of the correlation between FTO mutations and endometrial and ovarian cancer susceptibility.
کلیدواژه‌ها
Screening؛ FTO؛ Endometrial cancer؛ Ovarian cancer
سایر فایل های مرتبط با مقاله
مراجع
  1. Oranratanaphan S, Manchana T, Sirisabya N. Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis. Asian Pac J Cancer Prev. 2008;9(3):403-7.
  2. Ayyob AN, Al-Badran AI, Abood RA. Association of TTTA polymorphism in CYP19 gene with endometrial and ovarian cancers risk in Basrah. Gene Rep. 2019;16:100453.
  3. Loos R, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev. 2008;9(3):246-50.
  4. Gerken T, Girard CA, Tung Y-CL, Webby CJ, Saudek V, Hewitson KS, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469-72.
  5. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N 6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885-7.
  6. Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017;18(11):2622-34.
  1. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285-95.
  2. Toh JD, Sun L, Lau LZ, Tan J, Low JJ, Tang CW, et al. A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N 6-methyladenosine demethylase FTO. Chem Sci. 2015;6(1):112-22.
  3. Deng X, Su R, Stanford S, Chen J. Critical enzymatic functions of FTO in obesity and cancer. Front Endocrinol. 2018;9:396.
  4. Olszewski PK, Fredriksson R, Olszewska AM, Stephansson O, Alsiö J, Radomska KJ, et al. Hypothalamic FTO is associated with the regulation of energy intake not feeding reward. BMC Neurosci. 2009;10(1):1-12.
  5. Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013;45(4):428.
  6. Chen J. Multiple signal pathways in obesity‐associated cancer. Obes Rev. 2011;12(12):1063-70.
  7. Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 2012;319(1):89-97.
  8. Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, et al. FTO-dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 2020;80(16):3200-14.
  9. Reitz C, Tosto G, Mayeux R, Luchsinger JA, Group N-LNFS, Initiative tAsDN. Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease. PloS One. 2012;7(12):e50354.
  10. Zheng Z, Hong L, Huang X, Yang P, Li J, Ding Y, et al. Screening for coding variants in FTO and SH2B1 genes in Chinese patients with obesity. PloS One. 2013;8(6):e67039.
  11. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-9.
  12. Mojaver M, Mokarian F, Kazemi M, Salehi M. Specific TaqMan allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of FTO Gene demonstrated that there is no association between these SNPs and risk of breast cancer in Iranian women. Adv Biomed Res. 2015;4.
  1. Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei D, et al. Association of FTO mutations with risk and survival of breast cancer in a Chinese population. Dis Markers. 2015;2015.
  2. Zhao Z, Wen W, Michailidou K, Bolla MK, Wang Q, Zhang B, et al. Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control. 2016;27(5):679-93.
  3. Lin Y, Ueda J, Yagyu K, Ishii H, Ueno M, Egawa N, et al. Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case–control study in Japan. BMC Cancer. 2013;13(1):1-6.
  4. Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79-96. e11.
  1. Zou D, Dong L, Li C, Yin Z, Rao S, Zhou Q. The m6A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019;19(1):1-12.
  2. Zhu Y, Shen J, Gao L, Feng Y. Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 2016;35(4):2391-7.
  3. Wang J-y, Chen L-j, Qiang P. The potential role of N6-methyladenosine (m6A) demethylase fat mass and obesity-associated gene (FTO) in human cancers. Onco Targets Ther. 2020;13:12845.
  4. Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY, et al. FTO regulates the chemo‐radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β‐catenin through mRNA demethylation. Molecular carcinogenesis. 2018;57(5):590-7.
  5. Lin Y-W, Yan M-D, Shih Y-L, Hsieh C-B. The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. Eur J Cancer. 2009;45(11):2041-9.
آمار
تعداد مشاهده مقاله: 957
تعداد دریافت فایل اصل مقاله: 368


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب